pharma · Chronic Diabetic Foot Ulcers · Diabetic Foot Infection · LABT
Lakewood-Amedex Biotherapeutics
Lakewood-Amedex Biotherapeutics is a pharma organization headquartered in University Park, USA. It trades on NYSE under ticker LABT. Primary therapeutic focus areas include Chronic Diabetic Foot Ulcers, Diabetic Foot Inf
University Park, USA HQ
8 Employees
Public company Type
LABT · NYSE Ticker
Company details
- Status
- Public
- HQ
- University Park, USA
- Employees
- 8
- Programs
- 4
- Drugs
- 1
- Patents
- 18
Bisphosphocin Nu-3
Phase 2 · small molecule · Diabetic Foot Infections
Bisphosphocin Nu-3 for Diabetic Foot Infections is a Phase 2 program (small_molecule) at Lakewood-Amedex Biotherapeutics with 1 ClinicalTrials.gov record(s).
Internal code LAI2014-1
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lakewood-Amedex Biotherapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Diabetic Foot Infections
- Status
- completed
- Trials
- 1